AstraZeneca Plans New API Manufacturing Facility in Ireland

September 22, 2021

AstraZeneca said it plans to establish an active pharmaceutical ingredient (API) manufacturing plant for small molecules in Ireland.

The goal of the $360 million investment is to reduce time to drug commercialization, lower costs and enable more sustainable manufacturing processes, the Anglo-Swedish drugmaker said.

The APIs will include “compounds with highly complex synthesis, requiring next-generation technologies and capabilities that can respond quickly and nimbly to rapidly changing clinical and commercial needs,” said Pam Cheng, the company’s executive vice president of global operations and IT.

View today's stories